UNSPSC 51422342: Dexamethasone sodium phosphate

This classification denotes a therapeutic glucocorticoid with the molecular formula C22H28FO8P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AI9376Y64P, chemically known as 16-alpha-methyl-9-alpha-fluoro-1,4-pregnadiene-11-beta,17-alpha,21-triol-3,20-dione but more generally known as dexamethasone sodium phosphate, which bears US NIH Compound Identifier 5743. European Medicines Agency schedules Dexamethasone sodium phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01615MIG.

UNSPSC 51422342 Dexamethasone sodium phosphate is a Commodity code used to classify pharmaceutical products, though recent state and local solicitation activity tagged under this code does not reflect procurement of dexamethasone itself. Instead, Seminole County, Florida has posted an IFB (Invitation for Bid) for naloxone and safe drug deactivation systems — a mismatch between the code's nominal pharmaceutical scope and the actual goods being procured. The code appears to see limited recent activity aligned with its stated purpose in state and local government contracting.

Seminole County released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The response deadline was July 26, 2023, and the contract includes a two-year initial term with a one-year renewal option. Vendors must submit bids through the county's e-Procurement Portal, include all shipping and delivery costs in their proposals, provide unit pricing for each line item, and comply with E-Verify, drug-free workplace certification, and applicable federal regulations including the Clean Air Act and Federal Water Pollution Control Act. The procurement does not designate explicit set-asides for disadvantaged enterprises. Given the narrow recent-opportunity record and the mismatch between the code's pharmaceutical classification and the naloxone-and-systems scope of the one visible solicitation, pursuit activity under this specific code warrants verification that your firm's product or service aligns with how individual procurement offices are actually tagging their buys.